Children with cavernous malformations face unique treatment challenges due to factors such as the malformation's location, size, risk of bleeding, and the complexities of pediatric tissue development.

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.